NTAP
27
4
AFL
49
3
UAL
44
3
STT
50
3
SNA
65
5
DIS
57
3
HST
33
5
ADBE
52
-2
PDCO
46
-3
GD
55
-4
TRIP
50
3
MA
58
3
PXD
65
12
COP
51
3
OKE
67
2
ZION
52
2
MAS
48
2
MCHP
68
3
DFS
47
8
URI
68
3
NTAP
27
4
AFL
49
3
UAL
44
3
STT
50
3
SNA
65
5
DIS
57
3
HST
33
5
ADBE
52
-2
PDCO
46
-3
GD
55
-4
TRIP
50
3
MA
58
3
PXD
65
12
COP
51
3
OKE
67
2
ZION
52
2
MAS
48
2
MCHP
68
3
DFS
47
8
URI
68
3
Financhill
Back

Keros Therapeutics 10K Form

Sell
49

KROS
Keros Therapeutics

Last Price:
42.08
Seasonality Move:
-32.26%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive KROS News And Ratings

See the #1 stock for the next 7 days that we like better than KROS

KROS Financial Statistics

Sales & Book Value

Annual Sales: $20.1M
Cash Flow: $-21.79M
Price / Cash Flow: 0
Annual Sales: $10.07
Price / Book: 4.47

Profitability

EPS (TTM): -4.15000
Net Income (TTM): $-104.68M
Gross Margin: --
Return on Equity: 0%
Return on Assets: 0%

Keros Therapeutics Earnings Forecast

Key Keros Therapeutics Financial Ratios

  • The Interest Expense is 0.00% of Operating Income.
  • Per Share Earnings over the last 5 years have been positive in 1 years.

Keros Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Healthcare
Current Symbol: KROS
CUSIP: 492327
Website: kerostx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

KROS Technical Analysis vs Fundamental Analysis

Sell
49
Keros Therapeutics (KROS) is a Sell

Is Keros Therapeutics a Buy or a Sell?